Atlas Trials

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Clinical trial NCT00939627 · COMPLETED

Trial details

NCT number
NCT00939627
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell Carcinoma
Start date
2009-07-01
Primary completion
2013-01-01
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.